Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
about
Health economic aspects of breast cancer treatment: the compulsory health insurances' viewIs blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) andTime-dependent endpoints as predictors of overall survival in multiple myelomaMultivariate meta-analysis using individual participant data.Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective.Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741The ARCAD clinical trials program: an update and invitation.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Design considerations on the proof of efficacy of functional foods.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
P2860
Q26826505-AEBA8E54-3655-427C-BD32-64C975BD38EDQ27025943-6175A87A-3532-4EAE-BDCA-D39567E76156Q30538040-2AF2751A-FE07-454C-9D94-389AF8321FCAQ30976009-B69013BE-0035-4078-8BFD-96397C81FC17Q33800697-066E178A-526B-46AD-9334-EC5C572D951DQ35223628-8746053F-5D5B-4D1A-836F-A6CE6CFB3977Q35584926-3B7A8100-D282-4A8A-8BF3-4A080F42B3E9Q35776224-2E546661-1735-439C-92F2-FA893BAAF5C7Q36181578-2A43D244-A945-4884-8AB5-F668A601F563Q36349459-1774E618-318B-4740-B344-DB288856E3B7Q37937696-A46F1DED-E0D4-4A42-AC23-11101090E4ECQ38259501-C332E2ED-819E-481E-929C-6D7810205B1EQ39295492-4B8B77AD-46D6-41C7-8341-FDF01BD11DB8Q47591645-FB61B0BE-BE40-4465-A595-63DDBE8FCDD2
P2860
Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of meta-analysis for the v ...... d biomarkers in cancer trials.
@en
Use of meta-analysis for the v ...... d biomarkers in cancer trials.
@nl
type
label
Use of meta-analysis for the v ...... d biomarkers in cancer trials.
@en
Use of meta-analysis for the v ...... d biomarkers in cancer trials.
@nl
prefLabel
Use of meta-analysis for the v ...... d biomarkers in cancer trials.
@en
Use of meta-analysis for the v ...... d biomarkers in cancer trials.
@nl
P1433
P1476
Use of meta-analysis for the v ...... d biomarkers in cancer trials.
@en
P304
P356
10.1097/PPO.0B013E3181B9C602
P50
P577
2009-09-01T00:00:00Z